Get the Stockscreener App
2.02
7.34%
-0.16
After Hours:
2.02
Bioaffinity Technologies Inc stock is traded at $2.02, with a volume of 257.14K.
It is down -7.34% in the last 24 hours and down -48.47% over the past month.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
See More
Previous Close:
$2.18
Open:
$2.15
24h Volume:
257.14K
Relative Volume:
0.03
Market Cap:
$9.09M
Revenue:
$6.16M
Net Income/Loss:
$-14.91M
P/E Ratio:
-0.1893
EPS:
-10.6693
Net Cash Flow:
$-9.39M
1W Performance:
-24.06%
1M Performance:
-48.47%
6M Performance:
-6.91%
1Y Performance:
-82.28%
1-Day Range:
$2.00
$2.15
1-Week Range:
$2.00
$2.65
52-Week Range:
$0.693
$15.00
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
Name
Bioaffinity Technologies Inc
Sector
Industry
Phone
210-698-5334
Address
3300 NACOGDOCHES ROAD, SAN ANTONIO
Compare BIAF vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
2.02 | 9.81M | 6.16M | -14.91M | -9.39M | -10.67 |
TMO
Thermo Fisher Scientific Inc
|
466.76 | 171.91B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
174.63 | 123.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.97 | 44.73B | 4.30B | 1.06B | 1.04B | 13.08 |
WAT
Waters Corp
|
342.75 | 29.63B | 3.17B | 642.63M | 516.49M | 10.77 |
A
Agilent Technologies Inc
|
117.53 | 31.70B | 7.07B | 1.29B | 993.00M | 4.5355 |
Bioaffinity Technologies Inc Stock (BIAF) Latest News
symbol__ Stock Quote Price and Forecast - CNN
bioAffinity Shareholders Approve Equity Plan and Capital Measures - TipRanks
Investors in bioAffinity (NASDAQ: BIAF) register 497,483 shares for resale - Stock Titan
bioAffinity Technologies (BIAF) wins approval for major equity plan, offerings and reverse split - Stock Titan
BioAffinity stock surges 113.8% in 3 months: What's driving the rally? - MSN
bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment - BioSpace
BIAF Stock Dips After Q3 Earnings Reflect Lower Sales and Wider Loss - MSN
BIAF stock gains as CyPath sales surge 146% in Q1 - MSN
bioAffinity Technologies prices $4.8 million public offering; shares down over 30% - MSN
bioAffinity Technologies Working With U.S. Army on CyPath Lung Study - Medical Product Outsourcing
BioAffinity (BIAF) Stock in Focus Today (Volatility Increases) 2026-04-20Trading Community - Cổng thông tin điện tử tỉnh Lào Cai
BioAffinity shares rise as CyPath Lung growth boosts optimism - MSN
BioAffinity (BIAF) Stock Slides (Breakdown Watch) 2026-04-16Shared Momentum Picks - Cổng thông tin điện tử Tỉnh Sơn La
bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally? - The Globe and Mail
New Case Study Shows bioAffinity Technologies CyPath Lung Diagnostic Helps Avoid Unnecessary Lung Biopsy - National Today
CyPath® Lung Diagnostic Helps Defer Unnecessary Biopsy - National Today
New Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy - BioSpace
New Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, P - PharmiWeb.com
bioAffinity Highlights CyPath Lung Case Avoiding Unnecessary Biopsy - TipRanks
CyPath Lung case study at bioAffinity (NASDAQ: BIAF) shows biopsy deferred - Stock Titan
UGRO, TURB, ANNA, EEIQ, BIAF: These five stocks outpaced big tech with massive March returns - MSN
Institution Moves: Can bioAffinity Technologies Inc lead its sector in growth2026 Trading Volume Trends & Weekly Watchlist of Top Performers - baoquankhu1.vn
Investment Review: Is bioAffinity Technologies Inc Equity Warrant stock overvalued or fairly priced2026 Buyback Activity & Technical Pattern Based Buy Signals - baoquankhu1.vn
BIAF PE Ratio & Valuation, Is BIAF Overvalued - Intellectia AI
Wall Street Recap: Can bioAffinity Technologies Inc Equity Warrant outperform under higher oil pricesMarket Performance Report & Low Drawdown Investment Ideas - baoquankhu1.vn
Jobs Data: What hedge funds are buying bioAffinity Technologies Inc Equity WarrantWeekly Trading Summary & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
What is the volatility of BioAffinity (BIAF) Stock | Price at $3.54, Up 6.66%Growth Investing - Cổng thông tin điện tử Tỉnh Sơn La
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early - PharmiWeb.com
bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16 - BioSpace
bioAffinity Showcases CyPath Lung Test at Cleveland Clinic - TipRanks
CyPath Lung spotlight for bioAffinity Technologies (Nasdaq: BIAF) - Stock Titan
Risk Analysis: What are the future prospects of bioAffinity Technologies Inc Equity Warrant2026 Trading Recap & Community Consensus Trade Signals - baoquankhu1.vn
Is BioAffinity (BIAF) Stock Showing Strength | Price at $3.88, Down 1.02%Hot Market Picks - Cổng thông tin điện tử Tỉnh Sơn La
BIAFW Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
BIAF Stock Gains As CyPath Sales Surge 146% In Q1 - stocktwits.com
BIAF Should I Buy - Intellectia AI
bioAffinity Technologies, Inc.Common Stock (NQ: BIAF - The Chronicle-Journal
BIAF Stock Price $3.76 | bioAffinity Technologies, Inc. Live Quote - Meyka
bioAffinity reports 146% jump in Q1 lung test sales By Investing.com - Investing.com South Africa
Bioaffinity Technologies Inc Stock (BIAF) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):